<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351948</url>
  </required_header>
  <id_info>
    <org_study_id>VAC044</org_study_id>
    <nct_id>NCT01351948</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909</brief_title>
  <official_title>A Phase Ia Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines; AdCh63 AMA1, MVA AMA1 &amp; AMA1-C1/Alhydrogel® +/- CPG 7909</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the safety and immunogenicity of AdCh63 AMA1 and MVA AMA1vaccine&#xD;
      candidates administered alone and with adjuvants in various schedules. These vaccines consist&#xD;
      of inactivated viruses which have been modified, so they cannot reproduce in humans, and also&#xD;
      to include genetic material for malaria protein AMA1 which is expressed by the malaria&#xD;
      parasite during blood stage infection. The vaccines are designed to stimulate an immune&#xD;
      response to this malaria protein and thus provide protection against malaria infection.&#xD;
      Adjuvants are a crucial component of modern vaccine regimens, increasing the immunogenicity&#xD;
      and potency of protein vaccines. In this study we will assess whether virus vectored vaccines&#xD;
      combined with protein in adjuvant AMA1-C1/Alhydrogel® and CPG 7909 adjuvant (emulsion&#xD;
      containing TLR agonist) can induce stronger and more durable immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of vaccination</measure>
    <time_frame>Expected average of 12 months</time_frame>
    <description>To assess the safety of vaccination of healthy adults with AdCh63 AMA1, MVA AMA1 &amp; AMA1-C1/Alhydrogel® +/- CPG 7909 administered in various schedules using actively and passively collected data on adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of vaccination</measure>
    <time_frame>Expected average of 12 months</time_frame>
    <description>To assess the immunogenicity of vaccination of healthy adults with AdCh63 AMA1, MVA AMA1 &amp; AMA1-C1/Alhydrogel® +/- CPG 7909 administered in various schedules by measuring T cell responses (IFN-γ ELISPOT, flow cytometry), B cell responses and antibody responses to AMA1. Further immunological assessments may be undertaken as necessary</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdCh63 AMA1 + AMA1-C1/Alhydrogel®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdCh63 AMA1 + MVA AMA1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909</intervention_name>
    <description>5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909</intervention_name>
    <description>5x10^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 AMA1 + AMA1-C1/Alhydrogel®</intervention_name>
    <description>5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909</intervention_name>
    <description>5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdCh63 AMA1 + MVA AMA1</intervention_name>
    <description>5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 112. IM injections</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18 to 50 years&#xD;
&#xD;
          -  Able and willing (in the Investigator's opinion) to comply with all study requirements&#xD;
&#xD;
          -  Willing to allow the investigators to discuss the volunteer's medical history with&#xD;
             their General Practitioner&#xD;
&#xD;
          -  Women only: Must practice continuous effective contraception for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Men only: Must use barrier contraception from day of any vaccination with CPG 7909,&#xD;
             for 3 months.&#xD;
&#xD;
          -  Agreement to refrain from blood donation during the course of the study and for 6&#xD;
             months after the end of their involvement in the study.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinical P. falciparum malaria&#xD;
&#xD;
          -  Travel to a malaria endemic region during the study period or within the preceding six&#xD;
             months with a significant risk of malaria exposure.&#xD;
&#xD;
          -  Participation in another research study involving an investigational product in the 30&#xD;
             days preceding enrolment, or planned use during the study period.&#xD;
&#xD;
          -  Prior receipt of an investigational malaria vaccine or any other investigational&#xD;
             vaccine likely to impact on interpretation of the trial data.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the planned administration of the vaccine candidate.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV&#xD;
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)&#xD;
             immunosuppressant medication within the past 6 months (inhaled and topical steroids&#xD;
             are allowed)&#xD;
&#xD;
          -  Pregnancy, lactation or intention to become pregnant during the study&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine e.g. egg products, Kathon.&#xD;
&#xD;
          -  History of clinically significant contact dermatitis.&#xD;
&#xD;
          -  History of a known allergy to nickel (volunteers may be enrolled in group 5 if they&#xD;
             have an allergy to nickel)&#xD;
&#xD;
          -  Any history of anaphylaxis post vaccination.&#xD;
&#xD;
          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ).&#xD;
&#xD;
          -  History of serious psychiatric condition that may affect participation in the study.&#xD;
&#xD;
          -  Any other serious chronic illness requiring hospital specialist supervision.&#xD;
&#xD;
          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater&#xD;
             than 42 units every week.&#xD;
&#xD;
          -  Suspected or known injecting drug abuse in the 5 years preceding enrolment.&#xD;
&#xD;
          -  Seropositive for hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
          -  Seropositive for hepatitis C virus (antibodies to HCV).&#xD;
&#xD;
          -  History or evidence of pre-existing autoimmune or antibody mediated disease or&#xD;
             laboratory evidence of possible autoimmune disease, defined as anti-dsDNA ≥ 25 IU/mL&#xD;
             or a positive antinuclear antibody (ANA) result at screening.&#xD;
&#xD;
          -  Any clinically significant abnormal finding on biochemistry or haematology blood&#xD;
             tests, urinalysis or clinical examination.&#xD;
&#xD;
          -  Any other significant disease, disorder or finding which may significantly increase&#xD;
             the risk to the volunteer because of participation in the study, affect the ability of&#xD;
             the volunteer to participate in the study or impair interpretation of the study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian VS Hill, D.Phil, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Jenner Institute, University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

